Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Expressive Writing Reduced Cancer-Related Symptoms in RCC Patients

January 27, 2014
By Leah Lawrence
Article

Expressive writing is a brief and simple intervention that a recent study showed helped to reduce cancer-related symptoms and improved physical functioning in patients with renal cell carcinoma.

Expressive writing is a brief and simple intervention that a recent study showed helped to reduce cancer-related symptoms and improved physical functioning in patients with renal cell carcinoma.

Considering the findings in light of an entirely self-administered, brief, safe, and virtually no-cost intervention, expressive writing appears to be a promising supportive care approach, according to study author Lorenzo Cohen, MD, of the University of Texas MD Anderson Cancer Center.

“Just four 20-minute sessions of expressive writing, writing about your deepest thoughts and feelings about a past traumatic event or an ongoing difficult life experience like the diagnosis and treatment of cancer, has been found to improve a diverse set of outcomes in both healthy people and those with cancer,” Cohen told Cancer Network.

Although prior studies with cancer patients have tended to be small and mainly conducted in women with breast cancer with early-stage disease, this study sought to determine the benefits of expressive writing in patients with kidney cancer, half of whom had advanced disease.

Cohen and colleagues enrolled 277 patients with stage I to stage IV renal cell carcinoma. Patients were randomly assigned to expressive writing or neutral writing-writing about neutral topics-on four occasions. At baseline and months 1, 4, and 10, the patients were tested for depression, fatigue, cancer-related symptoms, sleep, and other quality-of-life parameters using several different scales. Results of the study were published in the Journal of Clinical Oncology.

“Patients in the expressive writing group reported fewer cancer-related symptoms, moderately lower levels of fatigue, and higher physical function aspects of quality of life 10 months after the writing sessions compared to patients that were in a neutral writing group,” Cohen said.

Specifically, at 10 months the group assigned expressive writing had significantly better MD Anderson Symptoms Inventory scores compared with those assigned neutral writing (P = .003). Additionally, expressive writing resulted in higher physical component summary scores on the Medical Outcomes Study Short Form-36 at 10 months (P = .019).

“These beneficial effects were partly due to the expressive writing leading to lower intrusive thoughts (unbidden/unwanted thoughts about their cancer intruding in their lives) one month post-intervention,” Cohen said. “It was surprising to see that the effects emerged over time, as one would expect the effects of such a brief intervention to wane over time. However, it seems that expressive writing leads to better long-term outcomes through early improvements in cognitive processing.”

According to the researchers, future research should examine for whom expressive writing is most useful.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Related Content

A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.

Machine Learning Approach May Predict Outcomes in RCC

Kristie L. Kahl
June 4th 2025
Article

A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of prior immunotherapy or tyrosine kinase inhibitor use.

Second-Line Cabozantinib Regimens Exhibit Efficacy in Advanced RCC

Roman Fabbricatore
June 2nd 2025
Article

Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of patients' prior immunotherapy or tyrosine kinase inhibitor use.


Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Manojkumar Bupathi, MD, MS;Manojkumar Bupathi, MD, MS
May 1st 2025
Podcast

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.


Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.

FDA Approves Belzutifan in Adult/Pediatric Pheochromocytoma and Paraganglioma

Tim Cortese;Ariana Pelosci
May 14th 2025
Article

Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.


Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.

Durvalumab Combo Demonstrates DFS Improvement in High-Risk NMIBC

Roman Fabbricatore
May 9th 2025
Article

Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.

Related Content

A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.

Machine Learning Approach May Predict Outcomes in RCC

Kristie L. Kahl
June 4th 2025
Article

A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of prior immunotherapy or tyrosine kinase inhibitor use.

Second-Line Cabozantinib Regimens Exhibit Efficacy in Advanced RCC

Roman Fabbricatore
June 2nd 2025
Article

Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of patients' prior immunotherapy or tyrosine kinase inhibitor use.


Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Manojkumar Bupathi, MD, MS;Manojkumar Bupathi, MD, MS
May 1st 2025
Podcast

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.


Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.

FDA Approves Belzutifan in Adult/Pediatric Pheochromocytoma and Paraganglioma

Tim Cortese;Ariana Pelosci
May 14th 2025
Article

Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.


Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.

Durvalumab Combo Demonstrates DFS Improvement in High-Risk NMIBC

Roman Fabbricatore
May 9th 2025
Article

Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.